≡

Regulation Of Nuclear Pre-mRNA Domain Containing Protein 2 (RPRD2)

[Edit]

Regulation Of Nuclear Pre-mRNA Domain Containing Protein 2 (RPRD2)
CCC R928
HGNC 29039
MGI 1922387
UniProt Q5VT52
Wiki KIAA0460
RPRD2, Contains 1 CID domain. The beta-catenin inhibitory domain (CID) of APC located between the second and third 20 amino acid repeats and therefore present in many truncated APC products found in human tumours. In truncated APC, the CID is absolutely necessary to down-regulate the transcriptional activity and the level of beta-catenin, even when an axin/conductin binding site is present. The activity of the CID is dramatically reduced in several colon cancer cell lines and can be inhibited by shorter truncated APC lacking the CID.
The CID is a direct target of the selective pressure acting on APC during tumourigenesis. It explains the interdependence of both APC mutations, not only in colorectal but also in duodenal and desmoid tumours.

Organism species: Homo sapiens (Human)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Recombinant Regulation Of Nuclear Pre-mRNA Domain Containing Protein 2 (RPRD2) Recombinant Protein Customized Service Offer
Antibodies n/a Monoclonal Antibody to Regulation Of Nuclear Pre-mRNA Domain Containing Protein 2 (RPRD2) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Regulation Of Nuclear Pre-mRNA Domain Containing Protein 2 (RPRD2) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Regulation Of Nuclear Pre-mRNA Domain Containing Protein 2 (RPRD2) CLIA Kit Customized Service Offer
n/a ELISA Kit for Regulation Of Nuclear Pre-mRNA Domain Containing Protein 2 (RPRD2) ELISA Kit Customized Service Offer

Organism species: Mus musculus (Mouse)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Recombinant Regulation Of Nuclear Pre-mRNA Domain Containing Protein 2 (RPRD2) Recombinant Protein Customized Service Offer
Antibodies n/a Monoclonal Antibody to Regulation Of Nuclear Pre-mRNA Domain Containing Protein 2 (RPRD2) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Regulation Of Nuclear Pre-mRNA Domain Containing Protein 2 (RPRD2) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Regulation Of Nuclear Pre-mRNA Domain Containing Protein 2 (RPRD2) CLIA Kit Customized Service Offer
n/a ELISA Kit for Regulation Of Nuclear Pre-mRNA Domain Containing Protein 2 (RPRD2) ELISA Kit Customized Service Offer
  1. "Complete sequencing and characterization of 21,243 full-length human cDNAs." Nat. Genet. 36:40-45(2004) [PubMed] [Europe PMC] [Abstract]
  2. "The full-ORF clone resource of the German cDNA consortium."BMC Genomics 8:399-399(2007) [PubMed] [Europe PMC] [Abstract]
  3. "The DNA sequence and biological annotation of human chromosome 1." Nature 441:315-321(2006) [PubMed] [Europe PMC] [Abstract]
  4. "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]
  5. "Characterization of cDNA clones in size-fractionated cDNA libraries from human brain."DNA Res. 4:345-349(1997) [PubMed] [Europe PMC] [Abstract]
  6. "Construction of expression-ready cDNA clones for KIAA genes: manual curation of 330 KIAA cDNA clones."DNA Res. 9:99-106(2002) [PubMed] [Europe PMC] [Abstract]
  7. "Global, in vivo, and site-specific phosphorylation dynamics in signaling networks."Cell 127:635-648(2006) [PubMed] [Europe PMC] [Abstract]
  8. "A probability-based approach for high-throughput protein phosphorylation analysis and site localization."Nat. Biotechnol. 24:1285-1292(2006) [PubMed] [Europe PMC] [Abstract]
  9. "Phosphorylation analysis of primary human T lymphocytes using sequential IMAC and titanium oxide enrichment."J. Proteome Res. 7:5167-5176(2008) [PubMed] [Europe PMC] [Abstract]
  10. "A quantitative atlas of mitotic phosphorylation."Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008) [PubMed] [Europe PMC] [Abstract]
  11. "Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach."Anal. Chem. 81:4493-4501(2009) [PubMed] [Europe PMC] [Abstract]
  12. "Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions."Sci. Signal. 2:RA46-RA46(2009) [PubMed] [Europe PMC] [Abstract]
  13. "Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis."Sci. Signal. 3:RA3-RA3(2010) [PubMed] [Europe PMC] [Abstract]
  14. "Initial characterization of the human central proteome."BMC Syst. Biol. 5:17-17(2011) [PubMed] [Europe PMC] [Abstract]
  15. "System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation."Sci. Signal. 4:RS3-RS3(2011) [PubMed] [Europe PMC] [Abstract]
  16. "Control of the RNA polymerase II phosphorylation state in promoter regions by CTD interaction domain-containing proteins RPRD1A and RPRD1B."Transcription 2:237-242(2011) [PubMed] [Europe PMC] [Abstract]
  17. "N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB."Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012) [PubMed] [Europe PMC] [Abstract]
  18. "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome."J. Proteomics 96:253-262(2014) [PubMed] [Europe PMC] [Abstract]